Schizoaffective Disorder - Pipeline Insight, 2024

This “Schizoaffective Disorder - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Schizoaffective disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Schizoaffective disorder: Understanding

Schizoaffective disorder: Overview

Schizoaffective disorder is a chronic mental health condition characterized primarily by symptoms of schizophrenia, such as hallucinations or delusions, and symptoms of a mood disorder, such as mania and depression. The symptoms of schizoaffective disorder can be severe and need to be monitored closely. Depending on the type of mood disorder diagnosed, depression or bipolar disorder, people will experience different symptoms: Hallucinations, delusions, disorganized thinking, manic behavior, and depressed mood. The exact cause of schizoaffective disorder is unknown. A combination of causes may contribute to the development of schizoaffective disorder. Schizoaffective disorder can be difficult to diagnose because it has symptoms of both schizophrenia and either depression or bipolar disorder. Schizoaffective disorder is treated and managed in several ways: Medications, including mood stabilizers, antipsychotic medications and antidepressants, Psychotherapy, such as cognitive behavioral therapy or family-focused therapy, and Self-management strategies and education.

Schizoaffective disorder - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Schizoaffective disorder pipeline landscape is provided which includes the disease overview and Schizoaffective disorder treatment guidelines. The assessment part of the report embraces, in depth Schizoaffective disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Schizoaffective disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Schizoaffective disorder R&D. The therapies under development are focused on novel approaches to treat/improve Schizoaffective disorder.

Schizoaffective disorder Emerging Drugs Chapters

This segment of the Schizoaffective disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Schizoaffective Disorder Emerging Drugs

Risperidone: Lyndra Therapeutics Risperidone (LYN-005) is an oral, extended release formulation, presented in a capsule dosage form with an aim of reducing the frequency of dosing orally-administered medications to once weekly or less. It is a dopamine D2 receptor antagonists and is currently under Phase II development for the treatment of schizoaffective disorder. Lyndra Therapeutics announced the positive outcome of an end-of-phase II meeting with the US Food and Drug Administration (FDA) suggesting a clear path to approval for its weekly risperidone for the treatment of schizophrenia and schizoaffective disorder, LYN-005. The company plans to initiate its pivotal program for LYN-005 in early 2022.

Schizoaffective disorder: Therapeutic Assessment

This segment of the report provides insights about the different Schizoaffective disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Schizoaffective disorder

There are approx. 4+ key companies which are developing the therapies for Schizoaffective disorder. The companies which have their Schizoaffective disorder drug candidates in the most advanced stage, i.e. Phase III include, Lyndra Therapeutics.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Schizoaffective disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Schizoaffective disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Schizoaffective disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Schizoaffective disorder drugs.

Schizoaffective disorder Report Insights

• Schizoaffective disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Schizoaffective disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Schizoaffective disorder drugs?
• How many Schizoaffective disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Schizoaffective disorder?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Schizoaffective disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Schizoaffective disorder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Lyndra Therapeutics
• Luye Pharma Group Ltd.
• Bio Xcel TherapeuticsInc
• Reviva Pharma

Key Products

• Risperidone
• LY03010
• BXCL501
• RP5063

This product will be delivered within 1-3 business days.